Guadecitabine offers limited advantage over other standards for high-risk AMLJune 26, 2019AMLLeukemia, Myelodysplasia, Transplantation
Rituximab and vemurafenib could challenge frontline chemotherapy for HCLJune 26, 2019Leukemia, Myelodysplasia, Transplantation
‘Robust antitumor immune responses’ observed in pediatric ALLJune 26, 2019ALLPediatricsLeukemia, Myelodysplasia, Transplantation
Risk model could help predict VTE in acute leukemiaJune 26, 2019ThrombosisLeukemia, Myelodysplasia, TransplantationAML
AML variants before transplant signal need for aggressive therapyJune 25, 2019AMLLeukemia, Myelodysplasia, Transplantation
For tough AML, half respond to selinexor plus chemotherapyJune 25, 2019AMLLeukemia, Myelodysplasia, Transplantation
Hedgehog signaling offers prognostic, therapeutic potential in CLLJune 25, 2019Leukemia, Myelodysplasia, Transplantation
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Durable transfusion independence in MDS with imetelstatJune 18, 2019Myelodysplastic SyndromeLeukemia, Myelodysplasia, Transplantation
Antibody targeting ‘do not eat me’ signals is active in AML, MDSJune 11, 2019AMLMyelodysplastic SyndromeLeukemia, Myelodysplasia, Transplantation
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapyJune 7, 2019Leukemia, Myelodysplasia, Transplantation
SC-PEG comparable to pegaspargase in young ALL/LL patientsJune 1, 2019ALLAggressive LymphomasLeukemia, Myelodysplasia, Transplantation
Low intensity bridging may be best path to CAR T in adult ALLJune 1, 2019ALLLeukemia, Myelodysplasia, Transplantation
Combo produces ‘best response rate’ after first relapse in kids with AMLJune 1, 2019AMLPediatricsLeukemia, Myelodysplasia, Transplantation
Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLLMay 29, 2019Leukemia, Myelodysplasia, Transplantation
